Charlie is Professor of Gastroenterology at the University of Edinburgh, a UK Research and Innovation Future Leaders Fellow (UKRIFLF) and Consultant Gastroenterologist in the Edinburgh IBD Unit. His clinical, teaching and research interests have been focused on inflammatory bowel disease (IBD) since 2003. He was awarded his PhD in the Genetics of IBD and the prestigious UEG Rising Star award in Gastroenterology, both in 2009. Following this he spent 10 years working as a full-time consultant gastroenterologist leading an increasingly busy and complex IBD clinic.
In 2019 Charlie was awarded the UKRIFLF, a personal fellowship worth £1.7m that enabled his transition to full-time academic gastroenterology. His research team are based in the Centre for Genomics and Experimental Medicine within the Institute of Genetics and Cancer at the University of Edinburgh. Charlie’s core mission is to improve outcomes for people living with IBD. His team are working on predicting outcomes in IBD, using routinely collected NHS data (the Lothian IBD Registry) and dedicated multi-modal prospective cohorts to build predictive models. He is Chief Investigator of the PREdiCCt study, which has recruited 2650 patients in clinical remission with detailed baseline phenotyping (clinical, psycho-social, lifestyle, environmental, dietary, microbiome and genomics) and a minimum of 24 months longitudinal follow-up. In addition to predicting outcomes, Charlie is integrating health apps and working with industry partners to disrupt IBD care through digital technologies and data driven innovation.
Charlie has been centrally involved with the European Crohn’s and Colitis Organisation over the last 10 years (EduCom 2009-2013; SciCom 2014-2018). He is the Chief Scientists Office specialty lead for Gastroenterology in Scotland (2017 to present) and current chair of the British Society of Gastroenterology IBD Clinical Research Group. He is a passionate educator lecturing widely about the current and future management of IBD, the causes and consequences of IBD, telemedicine and digital health.
Charlie is leading the UK IBD COVID-19 Working Group and is senior author of the group’s guidance published in GUT (https://gut.bmj.com/content/69/6/984.long).